NCT06870500 Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient
| NCT ID | NCT06870500 |
| Status | Recruiting |
| Phase | — |
| Sponsor | South Valley University |
| Condition | Psoriatic Arthritis |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-03-05 |
| Primary Completion | 2026-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-03-05 with a primary completion date of 2026-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Psoriasis is a chronic, immune-mediated, multisystemic, inflammatory disease caused by the interaction of multiple susceptibility genes and environmental factors that affects 1-3% of the population worldwide .Psoriasis also is a chronic inflammatory skin disease characterized by scaly indurated erythema. Psoriatic arthritis (PsA) is an autoimmune and chronic musculoskeletal disorder that is associated with psoriasis of the skin . Its presentation can vary from subtle manifestations to highly destructive forms. Joint pain, stiffness and swelling are the most common symptoms.
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 years and above. * Patients having psoriasis diagnosed clinically and who have a severity grade of moderate to severe, defined as a Psoriasis Area and Severity Index (PASI) score from 5- 10 % of body surface area, and involvement of greater than 10% of the body surface area (BSA) with or without psoriatic arthritis Exclusion Criteria: * Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus). * Pregnancy and lactation. * Patients currently undergoing immunosuppressive or systemic therapies. * Patients with known genetic disorders affect immune system function. * Patients with liver or kidney impairment. * Patients with allergy or contraindication to methotrexate. * Patients with active or uncontrolled infections, including chronic infections like tuberculosis.
Contact & Investigator
Essam El-Din Abd El-Aziz Mohamed Ahmed Nada, Professor
STUDY CHAIR
Dermatology, Venereology and Andrology Sohag university
Frequently Asked Questions
Who can join the NCT06870500 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Psoriatic Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06870500 currently recruiting?
Yes, NCT06870500 is actively recruiting participants. Contact the research team at omarahmed331166@yahoo.com for enrollment information.
Where is the NCT06870500 trial being conducted?
This trial is being conducted at Qina, Egypt.
Who is sponsoring the NCT06870500 clinical trial?
NCT06870500 is sponsored by South Valley University. The principal investigator is Essam El-Din Abd El-Aziz Mohamed Ahmed Nada, Professor at Dermatology, Venereology and Andrology Sohag university. The trial plans to enroll 50 participants.